GenSight Biologics, a biopharmaceutical company based in France, is developing gene therapies for rare diseases that cause blindness. The company has recently received approval in the UK for its Phase I/II PIONEER trial, which will test a treatment combining gene therapy with a visual stimulation device for people with retinitis pigmentosa, an incu (Read more...)